U.S. markets open in 3 hours 40 minutes
  • S&P Futures

    4,412.25
    -2.75 (-0.06%)
     
  • Dow Futures

    34,965.00
    -33.00 (-0.09%)
     
  • Nasdaq Futures

    15,055.75
    +9.50 (+0.06%)
     
  • Russell 2000 Futures

    2,215.60
    -3.80 (-0.17%)
     
  • Crude Oil

    70.33
    -0.23 (-0.33%)
     
  • Gold

    1,816.20
    +2.10 (+0.12%)
     
  • Silver

    25.74
    +0.16 (+0.62%)
     
  • EUR/USD

    1.1860
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.1760
    0.0000 (0.00%)
     
  • Vix

    18.24
    -1.22 (-6.27%)
     
  • GBP/USD

    1.3937
    +0.0022 (+0.16%)
     
  • USD/JPY

    109.1740
    +0.1240 (+0.11%)
     
  • BTC-USD

    37,814.88
    -659.59 (-1.71%)
     
  • CMC Crypto 200

    924.41
    -19.03 (-2.02%)
     
  • FTSE 100

    7,135.49
    +29.77 (+0.42%)
     
  • Nikkei 225

    27,584.08
    -57.75 (-0.21%)
     

Tauriga Sciences Inc. Increases Size of Initial Production Run for its Delta 8 THC Infused Tauri-Gum Version

·5 min read

04_20 PR Image

Delta 8 THC Tauri-Gum™ Blister Pack Sleeve
Delta 8 THC Tauri-Gum™ Blister Pack Sleeve
Delta 8 THC Tauri-Gum™ Blister Pack Sleeve


This Initial Production Run has Been Doubled, Due to Strong Indications of Demand & Pre-Orders

NEW YORK, NY, April 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry, Evergreen Mint), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has doubled the initial production run total(s) for its Delta 8 Tetrahydrocannabinol (“Delta 8 THC”) infused version of Tauri-Gum™ (9thoverall product line SKU). This Tauri-Gum™ product version is infused with 10mg of Delta 8 THC (per each piece of chewing gum) and is manufactured in Evergreen Mint flavor – MSRP per Blister Pack is $18.99.

The Company is experiencing strong levels of performance and growth in its retail business. The Company has already generated record monthly sales (by a substantial margin), for the month of April 2021 (in just 20 days of this month). Driving the record performance in its retail business are the following factors: continued strength in E-Commerce business segment, Pre-Orders for its enhanced 25mg CBD/CBG infused versions of Tauri-Gum™, and Pre-Orders for its Delta 8 THC infused version of Tauri-Gum™. The Company’s previous monthly sales record of approximately $47,000, was established during July 2020.

Lastly, the Company continues to realize important and material progress, with respect to its ongoing Pharmaceutical Development initiative. This initiative refers to the Company’s ongoing development of its proposed, Cannabinoid based, Pharmaceutical grade “Anti-Nausea” chewing gum, targeting nausea that emanates from ongoing chemotherapy treatment. The Company expects to issue additional update(s) to shareholders within the near term.

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.

The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.

DISCLAIMER -- Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.

4 Nancy Court, Suite 4

Wappingers Falls, NY 12590

Chief Executive Officer

Mr. Seth M. Shaw

Email: sshaw@tauriga.com

cell # (917) 796 9926

Company Instagram: @taurigum

Personal Instagram: @sethsms47

Twitter: @SethMShaw

Corp. Website: www.tauriga.com

E-Commerce Website: www.taurigum.com

Attachment